Nathanael R. Fillmore
Publications / 2022
paper
Blood2022doi:10.1182/blood.2022016317

Increased COVID-19 breakthrough infection risk in patients with plasma cell disorders.

Jennifer La†, Julie Tsu-Yu Wu†, Westyn Branch-Elliman, Linden Huhmann, Summer S. Han, Mary Brophy, Nhan V. Do, Albert Y. Lin, Nathanael R. Fillmore‡, Nikhil C. Munshi‡

† Equal first authorship · ‡ Equal senior authorship

Summary

Vaccinated patients with multiple myeloma and monoclonal gammopathy of undetermined significance (MGUS) face a significantly higher risk of breakthrough COVID-19 infections and severe disease compared to the general population. These findings suggest that both active malignancy and its precursor state impair vaccine response, highlighting a need for additional protective strategies in these patient populations.

Key result

Vaccinated patients with multiple myeloma and monoclonal gammopathy of undetermined significance exhibit an increased risk of SARS-CoV-2 breakthrough infections compared to matched controls.

Key figure

Key figure from Increased COVID-19 breakthrough infection risk in patients with plasma cell disorders.